The objective of this systematic review, which was performed following the guidelines of the Cochrane collaboration, was to assess the effects of interventions for treatment of atopic dermatitis (AD) in dogs. Citations identified from three databases (MEDLINE, Thomson’s Science Citation Index Expanded and CAB Abstracts) and trials published by December 2007 were selected. Proceedings books from the major veterinary dermatology international congresses were hand searched for relevant citations. The authors selected randomized controlled trials (RCTs), published from January 1980 to December 2007, which reported the efficacy of topical or systemic interventions for treatment or prevention of canine AD. Studies had to report assessments of either pruritus or skin lesions, or both. Studies were selected and data extracted by two reviewers, with discrepancies resolved by a third arbitrator. Missing data were requested from study authors of recently published trials. Pooling of results and meta‐analyses were performed for studies reporting similar interventions and outcome measures. A total of 49 RCTs were selected, which had enrolled 2126 dogs. This review found some evidence of efficacy of topical tacrolimus (3 RCTs), topical triamcinolone (1), oral glucocorticoids (5), oral ciclosporin (6), subcutaneous recombinant γ‐interferon (1) and subcutaneous allergen‐specific immunotherapy (3) to decrease pruritus and/or skin lesions of AD in dogs. One high‐quality RCT showed that an oral essential fatty acid supplement could reduce prednisolone consumption by approximately half. Additional RCTs of high design quality must be performed to remedy previous flaws and to test interventions for prevention of flares of this disease.
Over a period of one year, 251 dogs were presented to a UK-based dermatology referral clinic. Eighty-five of these were either diagnosed as having symptoms compatible with atopy (58 dogs), or suffered from chronic otitis or recurrent pyoderma. All 85 were placed on a carefully restricted diet for eight to nine weeks in an attempt to establish whether the symptoms were due to food sensitivity. In total, 19 were shown to have food sensitivity, representing 7.6 per cent of all dogs presented to the clinic, and one-third (32.7 per cent) of those dogs with signs compatible with a diagnosis of atopy. In five dogs with proven food sensitivity, otitis was the principal clinical sign and, in two others, recurrent pyoderma. In the population studied, labradors appeared to be predisposed to the condition. Improvement was monitored by asking owners to assess their dog's symptoms on an ordinal scale of pruritus. In those cases in which food sensitivity was confirmed, significant reduction in pruritus occurred. Most of these could be maintained long term on a commercial restricted-component diet. Particular effort was made to ensure owner compliance with the diet trials, using an explanation and model based upon a Venn diagram showing assumed links between atopy and several 'flare factors'. It was found that this approach significantly enhanced client understanding and cooperation. It is concluded that a careful approach, monitored by active clinical audit, will help to establish the true incidence of food sensitivity.
In humans, transepidermal water loss (TEWL) is measured by noninvasive techniques using either open- or closed-chamber instruments. The aim of this study was to investigate the use of a hand-held, closed chamber device (Vapometer) to measure TEWL in canine skin. Repeated measurements obtained from multiple body sites in one short and one long-coated dog had mean coefficients of variation ranging from 20% to 33%. In the short-coated dog, TEWL ranged from a mean of 5.8 g/m(2)/h on the ventral abdomen to 24.4 g/m(2)/h between the shoulders. In the long-coated dog, mean TEWL values ranged from 26.3 g/m(2)/h on the right chest wall to 51.3 g/m(2)/h in the right axilla. TEWL readings differed significantly at different body sites and showed significant day-to-day variation. In a comparison of a further 20 dogs, TEWL readings obtained from the lateral thorax differed significantly between dogs. Furthermore, in seven of the twenty dogs, readings differed significantly when one side was compared with the other. The Vapometer was able to measure TEWL in canine skin and yielded values similar to those previously reported in the literature using other devices. However, for use in clinical studies, the significant site to site, day-to-day and dog to dog variations would make changes induced by disease, drugs, dietary supplements or topical agents very difficult to reliably detect.
A form of Demodex species mite shorter in length than Demodex canis was found in six consecutive cases of canine demodicosis. The mean length of the parasite was 122.6 microns (SD 12.0 microns, 39 mites counted), significantly shorter than either male or female forms of D canis (P < 0.0001). The proportion of short to long mites in each case varied from 0.5 to 22 per 100. In young dogs, skin signs associated with the presence of mites were first noted after about seven months, while in the oldest subject the disease became apparent at 10 years of age. This form of mite has now been found in four countries over three continents, the findings suggesting that it is not uncommon and is acquired in puppyhood, although it may be carried unnoticed for many years.
The available reports upon the occurrence of mites of the Demodicidae in the cat are reviewed and current knowledge of the biology is discussed. The conclusion is drawn that demodicosis of the cat is more prevalent than previously supposed. It is found in both male and female, in long-and shorthaired coat types, and in several breeds. Infestation may be found in the absence of frank signs, or it may be associated with systemic diseases. However, it remains unclear whether the parasite can itself cause clinically apparent disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.